: *
!"
#$% & '( ) *+*, -
&.
:/+ 0 [email protected]
3
E SIRT1
hTERT hs-
! "
CRP:
CAD$
%& ' (
)
1 2
! 3
" # $ 1
! 4
&
'
1 ( *
1 - ! "#$
%! & ' ()*
$+ , - . -
2 - 0 $
. . %. 1 '"%)*
2 1 3 4!
' ()*
%! &
# -
3 -
"#$
!
%! & ' ()*
$+ , - . -
4 -
7)* 8
1 ! "#$ '"%)*
%! & ' ()*
$+ , - .
-
! / #
$%&'
# ! / ( 2
/ ' *
% 98
-% % / 80
: 28 / 1 / 98 :
1 / 4 / 98
: +,
- . / 0 1 2 3 +
4 5 6 7, 83
+ 9:5
;3 " # < ="
5 + # ">
hTERT
"9 7,
8?
-
?# ! A B ' C D ' 7 85 E A F+ 1 2 6' .+>
H & I 0 J 3
0 J # 5
# .K L ' "
6 E
# . .M SIRT1 # hTERT :N # 6 O2 hsCRP
" . 8? # 3 P# !
) .R -+> A (CAD
T# # :
-+::3 R3 >
' 6 BK 3 ' : U5 & "/ -+>
60 X H "
#+Y CAD - :Y
65 - 45 -# [ 3 + E '
R -+::3 4 L [ + H < \ 3 ] # 6 "'#
E ' (OP) R L 5 -+::3 4
L [ + < Y\
H 3 # 400 6 "'#IU E #(OE) ' R H ] -+::3 3
6 "'# ] # )E
(pp 0+
2
;,5 - .+ +>
" ' :
. .M SIRT1 -# [ :1 7' D OE
) 3 + ] 039 / 0 (P=
Y . .M hTERT Y
6 -# [ Y -+Y::3 R3 Y>
:1 0# (5 1 2 & I .R> +
' H 3 =:5 '
# :N 6
$5 ' D
# - .K '
"
6 Y:1 7 Y3 $: E ` 2Y
hsCRP [ # -#
#OP [OE ' + a 5 5 ) 008
/ 0
#P=
05 / 0 .(P=
$ " # c [
:
9
& I 3 + '
H 3
# # ' "
6 ( 0 J E
+
# Y . Y
Y "Y A B CAD
Y' C
D ' 7 . .M SIRT1 :N # 6 A B < =" = '
C ` 2 7 3 hsCRP
.+>
-M # + 83 :
# CAD ' "
6 H E 3 hsCRP SIRT1 hTERT
+,
' - )* ?. @ A B "*
"
C # . 1
0 * 7
$ 8
< D D1 ) 1 , .(
H;
?I1 J $ H * K 1
7
8 L
M N O
.
"
A &
"
1 >
H %
>
N+
J $ P
+ Q 8 R S 1 & 8R N > H
: . >
T
"
>
1
$ 4$ . P DNA :
U
>
V4 J $ 3
"A B 3> 1 C # . 3>
"* P "4*
?I1 0> J $
>
2 . &
% 8 H M 1 )P
W 0
"4>
) 2 .(
X :
>
S 1 &
:
>
>
- A + N;
$ A$ 1
B; NAD 3 D $ H * J $ "4! $ '"* 8
9
N N 1"
9 . :
>
- A Y R $ -ADP
N <
- 4 ."* ! NAD 7
[ * X
: '"! , 4!
: SIRT1-7 )
3 4 .(
X : + J $ >
-"!
V4 1 3 M ] 1
? N , 8RN > A$
FOXO
,Tubulin ,NF-kb S 1 & 1
:
>
. $ _ 9`
53 P
PGC-1a, PPAR
9 N 4
> 1 - A >
"* P
$ 4$ . : A
>
. $ 8A C # . ]
&
. .1 &
b - A B 1 N & &+
"
V4 3
"44 ) 5 6 .(
8 >
K% T
>
S 1 & 1 DNA : "4! $
# * 9 ! N 1
! W J $ 1 "*
0 &
"
1N 1
>
"* P . ' - )* ?. @ ' "*
& $ 74 -"!
. H
>
>
d
e = P
8# 0 *
$ *2 &
8
< D
D1 )
7 8 .(
* % 3A N 4 VW
SIRT1
*1 g -"! ' $ $ A
N -2
K*
N T ) hTERT 8# 0 * (
M 9
N )
9 : $ - 8P .(
"
( C i
3 M N O
* % 3A
>
$ j<
1 SIRT "* $ bcl2
W J $ 0
?W .
*+
3 . P N ) 10 .(
W
0 e
"
>
( C i 3
0> $ 74
.
"
@ 1
>
! + N O )
*1"
_ 1 :
>
&
0
$ # . H
W $ 1 >
>
"* P .
"
>
( C i 3
N H ?W NF-KB
H
W $ 1 >
>
#
"44 ) 11 12 1 .(
: *E C1 R - 4?$
'"44 H % )l VW J $ 1 '"! , 4! N+
H + N >
Q A
"
( N . P
: 1
A - H ?W $ E
>
. 4(
m4 ]
> -2 - $ L 0 * "*
*+
A
* "
"! $ ! ) 13 .(
$ $ R
%4 A B
"
0 * C # . 1
8#
N1 % 1 + ? b
8*
"4
$ 4$
: $
V*
H ?W "
N : X
1 C # . 0> J $ >
A B
"
$ $ ; < W 8
< D D1 N
M O V4 3 )>
&
.
B $ A$ 1
A
"
"I L $ . P
$ # . 1 +*
A
* "
>"
( C i 3
1 1 : 0 * 1 E
' . $ X
: 1 >
hTERT . VW
A B $ $
"
4d8> 1 C # . 1 :
L P
-+
1 $ >
A$
. $ H 8 N
% -"$
:
@
?.
$ e"> $ ( 98% L
3 L 1 n
$ -+
1 : E 1 $ $ - -2
>
SIRT1 1 hTERT 1
o@
hsCRP
$ $ ; < W 8
p1
< D *1
W P =
.
T# #
'"44 ! - 8 $ :
+ N . $ 4 W
8*1 $ '"! H 4 1 1 65
$ $ ; <
8
*1 p1 "* $ - # #! Q D $ '"44 ?R
$ 0 N 50
% ( W P 9D "g
% p1 N
*1 N ."* $ !
" $ - P"44 . @
?
I 4
<
."! W P * > P+
?
>
$ 1 1
A4R 9 ! ?. @ 4 ' 1"
65 - 45 H
98%
$ ( 3 1 1 :
$ E
- 8 $ ; <
<= CAD
1 - %8>
$ - 8 ( W P $ $
0 N 50
% 9D "g
% p1 N
*1 U*+ $ '"! $ L W P
, ' $ 9 8
. ?W rbg H M * 4 P"*N ' ! 1 H 8? >
"
?. @ 98% N > &
4 1 8 2 >
N 3 6 - 4 8 1 -+ 1 , " N 0 & b>
9
%8> $
$ s M $
? .
>
?. @ $ 1 1 "
$ $ ; $ 9 ! 8
"<
$ 1 - M
t; , X1
"
98% e
>
( 3 1 :l1
>
1 1 : H 8? 1 ! P ' E (
N . $ $
- 8 P ,
"
. ?W H 8? >
W
% 4 P"*N ' ! 1 ?. @ " H M , *
9% 1 & ."44 rbg :
8 ?. @ ' ()* p;,
%! &
s M ' 8! $ - # 23605
1 '"! Q
www.clinicaltrial.org
' 8! $
NCT02011906 . '" P <L
$ - 8 u1 $ v
W '1 P $ W
98% '"44 (
3 ) (OP W '"44 n ( 98%
3 1 1 : E (OE) 1
W ( < ;& '"44 3
1
1 < ;&
: E (PP) A
3 '1 P ."*"!
* N1 OP 4
1 g P _ H AT (
3 w 87 ) 1 g
720
P 1EPA 480 P
' 8> $ (DHA _
8*1 H AT 1
: W E
'1 P ."*
OE
* N1 4
1 g P _ H AT
( 3 w 87 ) 1 g
720 P
1 EPA 480 P
$ (DHA
' 8>
_ 1 g H AT "
IU400 1 : W E
'1 P 1 "*
H AT PP
>
1 g 8*1 ( 3 1
1 : W E
."*
: 98%
1 " $
' W .
"D
$ : $ 1 1 8 1 -N1 - 8
&
0 N K& 1
? , "
: 8* ."!
*"$ ' )
* W (BMI $
M $ H W N ' b )
"$ (
" + ) 14 .(
15 1 - , * 8*
"
- &
0 K& 1 , " N
-
! j 9 N 1
"
1N $ $ 8 W P
."!
10 N
:
$ - , N "R
H
>
* ,
@ A> _ )
N ' b $ (PBMC
W H % D $ N 1 W P D ' b
- , '"*
1
"
P x
"
'N "* - N 1 P
V l
HsCRP C°
-80
"#(*
P
"
K& . N
N "R - , N PBMC
N ' b $ RNA
Rneasy plus mini kit
!
Qiagen
O<M 1
98?.
P x
"
1
> RNA
x
'"!
4 - N W cDNA
80 -
"#(*
."*"!
j cDNA Quantitect reverse transcriptase
!
Qiagen
N
"! x RNA
98?. O<M '
A 7* 1 "! ,
Real-time PCR
20 -
"#(*
."!
-2
β-actin
-2 - 4 $
housekeeping
$ . W P D ' b <
$ - -2
>
H W N ?. @
ct
-ΔΔ
2 ' b P
"
.
& .
> 8 H1"R ' b
1
! ' 1+
'"
.
E#+
1 . 1 2 - (" ' ] 5
Gene name Sequence
Forward hTERT
CTGTACTTTGTCAAGGTGGATGTG
Reverse hTERT
CTGGAGGTCTGTCAAGGTAGAG
Forward SIRT1
GCCGGAAACAATACCTCCAC
Reverse SIRT1
ACACCCCAGCTCCAGTTAG
Forward β- actin
CCTGGCACCCAGCACAATGAAG
Reverse β- actin
CTAAGTCATAGTCCGCCT GAAG
K D K
7 1 9 W * N ' b $ ;M SPSS
-2 1 18
$ 1 W P =
= ] ' N >
(*
: 1
@,
? ) P ' b (SEM
"
- N+ N ' b $ .
Kolmongorov-Smirnov - $ H *
N y ' >
$ P
"
9, "?$ 1 9<D = $ z * A .
'1 P
>
+ - N+ N ' b $ 1 W & = x1Nt
e; , j A
N * '1 P '"! 7 >
- N+
ANOVA
P ' b
"
. : ?. @
P.value N 8
05 / 0 4? e; , - 4 $ +
&
W ."!
" '
N 65 $ 8
$ :
?. @ 3 $ b*
A$
$ -"!
- 8
1 2 - %* e $ b*
98% 9 P x , ?. @ N >
'"
1 : $ ?. @ 60
8% b*
9
> '1 P N " > "!
OP 1OE
# * PP $ ?. @ Q
20 21 1 19
$ b*
8
D . W P
H1"R 2
&1 *+ ) . _
V l 1
hsCRP
'1 P
>
# * 1 " $ ?. @ , "
'1 P OP
) 20 (n=
'1 P OE
) 21 (n=
'1 P PP
) 19 (n=
P value#
"D ) (cm 0 &
36 /
±1 04 / 169 19
/
±1 32 / 170 19
/
±1 32 / 170 623
/ 0
-N1
) (kg 0 &
68 /
±2 95 / 79 17
/
±2 54 / 78 87
/
±1 35 / 78 864
/ 0
K&
70 /
±2 13 / 80 14
/
±2 85 / 78 82
/
±1 23 / 79 916
/ 0
e; , 33
/ 0 18± / 0 30
/ 0 30± / 0 40
/ 0 88± / 0 322
/ 0
P value*
591 / 0 335
/ 0 139
/ 0
' 8*
) *"$
(BMI 0 &
83 /
±0 95 / 27 70
/
±0 08 / 27 61
/
±0 85 / 26 530
/ 0
K&
81 /
±0 00 / 28 66
/
±0 17 / 27 58
/
±0 14 / 27 616
/ 0
e; , 12
/ 0 05± / 0 10
/ 0 09± / 0 13
/ 0 29± / 0 318
/ 0
P value*
687 / 0 37
/ 0 17
/ 0
) 8 1 (cm 0 &
11 /
±2 72 / 98 58
/
±1 76 / 95 88
/
±1 18 / 96 479
/ 0
K&
01 /
±2 30 / 98 45
/
±1 64 / 95 88
/
±1 42 / 96 556
/ 0
e; , 45
/
±0 42 / 0 - 53
/
±0 12 / 0 - 39
/
±0 24 / 0 618
/ 0
P value*
359 / 0 827
/ 0 548
/ 0
): $ 1 (cm 0 &
59 /
±1 12 / 101 15
/
±1 33 / 100 80
/
±0 63 / 99 701
/ 0
K&
42 /
±1 75 / 100 23
/
±1 78 / 100 83
/
±0 37 / 99 644
/ 0
e; , 52
/
±0 37 / 0 - 54
/
±0 45 / 0 45
/
±0 26 / 0 - 455
/ 0
P value*
481 / 0 411
/ 0 567
/ 0
hsCRP (mg/dl) 0 &
48 /
±0 76 / 2 55
/
±0 12 / 3 45
/
±0 34 / 3 720
/ 0
K&
18 /
±0 80 / 1 23
/
±0 60 / 1 64
/
±0 57 / 3 001
/ 0
46 e; , /
±0 96 / 0 - 48
/
±0 21 / 1 - 64
/
±0 23 / 0 132
/ 0
P value*
050 / 0 008
/ 0 716
/ 0
? @, |: (* ±
- N+# ANOVA x1N - N+* |
" $
$ ?. @ : V* N '1 P (*
: 4 1
$ $ ; $ H M 8
< D 4? 1 b ! "* R1
Q $ ) 079
/ 0 1 P=
299 / 0 4d8> .(.P=
:
$ I g ?. @ :
'1 P
>
4? 1 b ?. @
V* N W
2 * !
>
1
>
$ 1 'U
1 t W :
1 C : 4 E 1 " $ ... 1
# *
"* R1 , "
. ! $ j< ) W
>
&1 *+
_ V l ' 8> $ hsCRP
" $ ?. @
98% N K& ' 1 1 '1 P
>
?. @
H1"R 2 '"> ) 9$ D @* 8> . '"! ' 1+
$ :
> &
&1 *+
_
# * 1 " $ '1 P 1
4d8> 1 ?. @ :
N '1 P -1 V*
> >
"%d N
'1 P
>
$ 4? 1 b (* '"> )
"
.
# *
" $ $ <A* ?. @ '1 P 3> ?. @
W '"44
"
( C i 3
'1 P 3> 1
W n '"44
"
( C i 3
1 1 : o@ E
hsCRP 4? @$
."! 3
W
>
$ $ ~ $ : -2 ?. @ '1 P 1 >
H1"R 3 '"> ) @* 8> . '"! ' 1+
P -
$ - -2 SIRT1
$ : '1 P
98%
$ ( 3 1 1 :
$ E
- 8 $ ; <
<= CAD
1 - %8>
4? M $ ?. @ - N+ . $ 1 b
Tukey
g R1 N :
4? e; ,
$ : '1 P
>
1 OE
) $PP 037 / 0
= .(P
# *
$ ?. @ : '1 P 4? 1 b ?. @
V* N -
$ - -2
hTERT .")* '"> )
H1"R 3 > -2 - $ $ ~ $ > W .
SIRT1
1
hTERT
?. @ > '1 P
'1 P OP
) 20 (n=
'1 P OE
) 21 (n=
'1 P PP
) 19 (n=
P value
SIRT1 31
/
±0 44 / 1 79
/
±0 77 / 2 16
/
±0 95 / 0 039
/ 0
hTERT 25
/ 1 89± / 1 50
/ 2 24± / 5 54
/ 0 63± / 1 158
/ 0
# c
$ "
[
98% I g ?. @ ( $
3 € €#4 €$
: € 1 $ ' 8>
€4? 0> € €$ €74 E
s @€
hsCRP
• $ Nt <. ." P '1 €P "! $
W ( '"44 3
1 1 : € €) $ 0> € E
s @
hsCRP
W '1 P $ <A*
€#4 '"€44
( 3 V* $ ."* 8* $ 7 ( "
3 Q
: 1 $
98 % 2 4 = $E
€74 "44
0> € O€ M N C €# . "€4 W 0> $ ."€* PCRP
98% L
: € 1 €$
€$E
€ s @€ 1
- €4 €$ . € ' €<* €$ L ] ?. @ CRP
?. @ H `
Aryaeian
98% - %8> 1 $
IU
: 1400
" $E
3 4? 0> $ 74 '
o@
"€ (* "€ X 1 + $ ; < W CRP
) 15 ?. @ .(
Bhattacharya
98% - %8> 1
$
IU 200
: 1
"€ €$E
2 o@€ ' € CRP
€4? €M €$ €* N + S 1 $ ; < - 8 $ 0>
) 16 z * .(
_ , . *+
' - )*
98%
: € 1 $ 0> € €$ €74 "€* E
4?
s @ PCRP
) 17 ( C €i >" .
( 3 * $ 74 1 ! $ # . "I = , "4*
: " . 0>
€ V* $ €# . >
IL-1 IL-12
1
TNF-α
"€€* P ) 18 : €€4d8> C €€i " €€ [ €€* :€€ .(
o@ "*
hsCRP
€$ €W ‚ € , €$
o@
hsCRP
"> 0> t $ )
19 .(
z *
)* ?. @ : -2 - € $ € -
€>
SIRT1
'"44 W '1 P n
( 3
: 1 1
€$ <A*E
4? M $ ( '1 P 1 ) $
€?. @ ."! $
w;<D . ) C €i >" € € "€* $ ' - )*
( 3 -2 - $ 0 W $ D
SIRT1
0 €W O€ M N
- $ - € ; bAW
?W 1 N €A.
€>2 W1 AMPK
O M : N 1 ' $ : € - € $ "€4*
0 €& >
"€4> 0> $ # . )
20 .(
SIRT1
€ €$ €D
- N H ?W N K&NFkB
€74 € ' $AMPK
m4 . 4( €€ €€# €€$
-2 - €€ $ 1NFkB
$ €€# . €€>
P ) 21 .(
SIRT1
: €4d8>
€74
€ & €# €$
H H : -+ L 1 '"! H 1"* >
74 >
N1 % 1 + QD 0> $
€P ) 22 w;<€D .(
- €)*
98% € $ '"! '
€ €( € 3
1 1
€ :
E
€€W €€$ €€74 0
$
€€
- -2
PGC1a
€€$ ; €€< €€W
$ 8 Q€ D *1 p1
€P ) 23
€7 * .(
€?. @
I g 4d8>
: 98% - )*
€( €$ € 3
€ 1
: 1
4? 7 J $E
-2 - € $ o@€
hTERT
8*
98% "4i > . P
n €( €$
3 1
: 1
w <A* 0 W J $E
-2 - € $ o@€ R 9$ D
hTERT
'1 P - 8 $
€ + ƒ . N " POE
W : 4? 0 €V4 €$ € €?. @ _ . <*
( L $ 3
€< D - €8 $ _ : 1 $
W '1 €€P €€ "€€ P v €€) "€€! €€7*
'"€€44
: &
"€ :
EPA+ DHA
y € € :
0 W $ -"! ' 1 "4 ! > -"! ' ( W 3 0>
W ) 24 ?. @ .(
( - )*
* N1 e 4 P"*N ' ! 3
P
( :l1 3
4? 0 W $ ~ <
N € . ?W
€€ %.
3. €€ H €€AP $ €€W >
€€P ) 25 .(
: 4d8>
Bermuda
€7 € "€* - €)* - %8> 1
: 1
$ 74 E
C €
-21"€* N € € . ?W
H - "8 * M >
: € 1 €7 . €P
E
s @ 0> $ 74 : 4d8>
mRNA hTERT
1 '"€!
0> €€ -+ €€ 1 & €€ . ?W )
26 €€i €€%4 .(
-2 - € $ o@ 0 W 3l I g ?. @
hTERT
'1 P - 8 $ 4? 0 W : OE
€<*
wt €8 g €$
M €€, :€€
H €€ N €€ €€ . ?W €€ "€€! $ >
: &PBMC
4d8> ."! $ :
€ €P € • A $
1 €$ €P L 9 N % #4 W
hTERT
C €# . € V* €( "? > W 1 ' $ *"€$ € . ?W 1 " €A B € D €i _ 8 A
: ? . €AP $ - 1 € €> H €M '"44
W
"! $ ) 24 .(
$ M * z : 98% - )* ?. @
( $ 3 1 1 :
"* E
€ - $
€ -
SIRT1
$ $ ; < W 8
*1 p1 W
0 L € '
€€4?
$
€€
- -2
hTERT
€€
: . "€€* €€W
4d8>
: 98%
( $ 3 1 1
€ :
"€* E
€$
- 3
-
hsCRP
€ wt €8 g - €4 €$
€ _ U €
€$ Q€ 4 1 C €€# . „ € 0> €
A B
"
'"
$ €$ ; €< €W '"!
€8
< D - D1 P D ' b .
+? # I/5
:€ €7* € € W N '21 €&
€
1 "€ H €8 1 €) 1 €84> " € w €= , "*
.3 ( T
98%
( $ 3 1 1 :
$ E
- 8 $ ; <
<= CAD
1 - %8>
References
1. Young I, Woodside J. Antioxidants in health and disease. J Clin Pathol.
2001;54(3):176-186.
2. Adams DH, Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nature Review Immunology.
2006;6(3):244-251.
3. Revollo JR, Grimm AA, Imai S-i. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem. 2004;279(49):50754-50763.
4. Zhang T, Berrocal JG, Frizzell KM, Gamble MJ, DuMond ME, Krishnakumar R, et al. Enzymes in the NAD+ salvage pathway regulate SIRT1 activity at target gene promoters. J Biol Chem.
2009;284(30):20408-20417.
5. Lavu S, Boss O, Elliott PJ, Lambert PD.
Sirtuins—novel therapeutic targets to treat age-associated diseases. Nature Reviews Drug Discovery. 2008;7(10):841-853.
6. Michan S, Sinclair D. Sirtuins in mammals:
insights into their biological function.
Biochem J. 2007;404(1):1-13.
7. Fuster JJ, Andrés V. Telomere biology and cardiovascular disease. Circ Res.
2006;99(11):1167-1180.
8. Fyhrquist F, Saijonmaa O. Telomere length and cardiovascular aging. Ann Med.
2012;44(sup1):S138-S142.
9. Yamashita S, Ogawa K, Ikei T, Udono M, Fujiki T, Katakura Y. SIRT1 prevents replicative senescence of normal human umbilical cord fibroblast through potentiating the transcription of human telomerase reverse transcriptase gene.
Biochem Biophys Res Commun.
2012;417(1):630-634.
10.López‐Diazguerrero NE, Pérez‐Figueroa GE, Martínez‐Garduño CM, Alarcón‐Aguilar A, Luna‐López A, Gutiérrez‐Ruiz MC, et al. Telomerase activity in response to mild oxidative stress.
Cell Biol Int. 2012;36(4):409-413.
11.Sun D, Krishnan A, Zaman K, Lawrence R, Bhattacharya A, Fernandes G. Dietary n‐3 fatty acids decrease osteoclastogenesis and loss of bone mass in ovariectomized mice. J Bone Miner Res. 2003;18(7):1206-1216.
12.Calder PC. Omega-3 fatty acids and inflammatory processes. Nutrients.
2010;2(3):355-374.
13.Azzi A, Breyer I, Feher M, Pastori M, Ricciarelli R, Spycher S, et al. Specific cellular responses to α-tocopherol. J Nutr.
2000;130(7):1649-1652.
14.Singh S, Ahlawat S, Pandya S, Prafull B.
Anthropometric measurements and body composition parameters of farm women in north Gujarat. Journal of Ergonomics.
2013;3(1):1-4.
15.Aryaeian N, Shahram F, Djalali M, Eshragian MR, Djazayeri A, Sarrafnejad A, et al. Effect of conjugated linoleic acid, vitamin E and their combination on lipid profiles and blood pressure of Iranian adults with active rheumatoid arthritis. Vasc Health Risk Manag. 2008;4(6):1423-1432.
16.Bhattacharya I, Saxena R, Gupta V.
Efficacy of vitamin E in knee osteoarthritis management of North Indian geriatric population. her Adv Musculoskelet Dis.
2012;4(1):11-19.
17.Saboori S, Shab-Bidar S, Speakman J, Rad EY, Djafarian K. Effect of vitamin E
supplementation on serum C-reactive protein level: a meta-analysis of randomized controlled trials. Eur J Clin Nutr.
2015;69(8):867-873.
18.Mori TA, Beilin LJ. Omega-3 fatty acids and inflammation. Curr Atheroscler Rep.
2004;6(6):461-467.
19.Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Willett WC, Rimm EB. Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation.
2003;108(2):155-160.
20.Xue B, Yang Z, Wang X, Shi H. Omega-3 polyunsaturated fatty acids antagonize macrophage inflammation via activation of AMPK/SIRT1 pathway. PloS one.
2012;7(10):e45990.
21.Yang Z, Kahn BB, Shi H, Xue B-z.
Macrophage α1 AMP-activated protein kinase (α1AMPK) antagonizes fatty acid- induced inflammation through SIRT1. J Biol Chem. 2010;285(25):19051-19059.
22.Ota H, Eto M, Kano MR, Ogawa S, Iijima K, Akishita M, et al. Cilostazol inhibits oxidative stress–induced premature senescence via upregulation of Sirt1 in human endothelial cells. Arterioscler Thromb Vasc Biol. 2008;28(9):1634-1639.
23.Saboori S, Koohdani F, Nematipour E, Rad EY, Saboor-Yaraghi A, Javanbakht M, et al.
Beneficial effects of omega-3 and vitamin E coadministration on gene expression of SIRT1 and PGC1α and serum antioxidant enzymes in patients with coronary artery disease. Nutrition, Metabolism and Cardiovascular Diseases. 2016;26(6):489- 494.
24.Farzaneh-Far R, Lin J, Epel ES, Harris WS, Blackburn EH, Whooley MA. Association of marine omega-3 fatty acid levels with telomeric aging in patients with coronary heart disease. Jama. 2010;303(3):250-257.
25.Ornish D, Lin J, Daubenmier J, Weidner G, Epel E, Kemp C, et al. Increased telomerase activity and comprehensive lifestyle changes: a pilot study. Lancet Oncol.
2008;9(11):1048-1057.
26.Bermudez Y, Ahmadi S, Lowell NE, Kruk PA. Vitamin E suppresses telomerase activity in ovarian cancer cells. Cancer Detect Prev. 2007;31(2):119-128.
98%
( $ 3 1 1 :
$ E
- 8 $ ; <
<= CAD
1 - %8>
Effects of omega 3 and vitamin E supplementation on Gene Expression of SIRT1, hTERT and serum level of hsCRP in CAD male patients: a
randomized clinical trial study
Saboori S1, Djalali M2, Falahi E3, Abbasnezhad A1, Roosta S4, Yousefi Rad E1*
1.Assistant professor, Nutritional Health Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran, [email protected]
2.Full Professor, Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.
3.Full Professor, Nutritional Health Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran.
4.Student Research Committee, School of Health and Nutrition, Lorestan University of Medical Sciences, Khorramabad, Iran.
Received: 17 April 2019 Accepted: 22 Jun 2019
Abstract
Background: Studies have shown that Sirtuins have critical roles in the regulation of inflammation and oxidative stress, while hTERT has a protective effect via increasing the length of telomers in cardiovascular disease. The aim of this study was to assess the effects of omega 3 and vitamin E supplementation on the gene expressions of SIRT1 and hTERT and serum hsCRP level in CAD patients.
Materials and Methods: Participants in this Randomized Clinical Trial consisted of 60 non- smoking male CAD patients, with age ranges 45- 65 years, who were categorized into three groups, receiving: 4g/day of omega 3 and vitamin E placebo (OP); omega 3 (4g/day) and vitamin E 400IU/day (OE); and omega 3 and vitamin E placebos (PP) for two months.
Results: Gene expression of SIRT1 increased significantly in the OE group (P = 0.039), but gene expression of hTERT was not significantly different between the study groups. Supplementation with omega 3 and also co-administration of these fatty acids with vitamin E significantly decreased hsCRP level in OP and OE groups (P=0.008 and P= 0.050, respectively).
Conclusion: Supplementation with omega 3 and vitamin E seems to include beneficial effects on CAD patients, possibly via increasing gene expression of SIRT1, and also by lowering inflammation through decreasing serum level of hsCRP in these patients.
Keywords: CAD, vitamin E, omega 3, hsCRP, SIRT1, hTERT.
*Citation: Saboori S, Djalali M, Falahi E, Abbasnezhad A, Roosta S, Yousefi Rad E. Effects of omega 3 and vitamin E supplementation on gene expressions of SIRT1, hTERT and serum level of hsCRP in CAD male patients: A randomized clinical trial study. Yafte. 2019; 21(2):84-92.
